Akriveia Therapeutics’ mission is to discover and develop better, safer immunotherapeutics.
Recent developments in cancer immunotherapy have yielded unprecedented results in a sub-set of patients with certain types of advanced tumors. This class of powerful new drugs work by counteracting the ability of many cancers to evade the patient’s immune system. Treatment with these new medicines restores the ability of the immune system to attack and directly kill the cancer cells. By unleashing the power of the immune system these new therapeutics have led to striking responses, even in advanced stage cancers; and in some instances, even to complete eradication of the cancer. These are wonderful results.
However, unleashing the patient’s own immune system to fight cancer frequently comes at a heavy price. Once activated, the patient’s immune system will often attack not only cancer cells but also healthy tissues. This attack can cause serious side effects which impose severe limitations on dosing, treatment duration and, potentially, efficacy. In addition, immune-related side-effects can substantially compromise the post-treatment well-being of patients, with some patients suffering life-long and debilitating consequences from their treatment.
Akriveia Therapeutics’ proprietary Aklusion™ platform addresses this limitation by restricting the action of the therapeutic agent to just the location of the tumor. Akriveia’s approach may enable potentially curative immunotherapeutic agents to be given to more patients, for longer duration of treatment and using the most potent combinations of drugs to maximize the probability of durable therapeutic responses.
Akriveia was founded in 2015 and has licensed key technology from Thomas Jefferson University and City of Hope. The company is backed by top-tier venture investors, has an experienced management team and is building operations in Cambridge, Massachusetts.